12/19
07:50 am
xlo
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI [Yahoo! Finance]
Medium
Report
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI [Yahoo! Finance]
12/19
07:30 am
xlo
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Medium
Report
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
12/16
07:47 am
xlo
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer [Yahoo! Finance]
Medium
Report
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer [Yahoo! Finance]
12/16
07:30 am
xlo
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Medium
Report
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
12/9
11:58 am
xlo
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright [Yahoo! Finance]
Low
Report
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright [Yahoo! Finance]
12/3
04:38 pm
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/3
04:30 pm
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/8
01:44 pm
xlo
Xilio Therapeutics, Inc. (NASDAQ: XLO) had its price target lowered by analysts at Raymond James from $6.00 to $4.00. They now have an "outperform" rating on the stock.
Low
Report
Xilio Therapeutics, Inc. (NASDAQ: XLO) had its price target lowered by analysts at Raymond James from $6.00 to $4.00. They now have an "outperform" rating on the stock.
11/7
09:15 am
xlo
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
High
Report
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
11/7
09:09 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results [Yahoo! Finance]
11/7
09:05 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
High
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
10/30
09:01 am
xlo
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
High
Report
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
10/21
08:29 am
xlo
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4's NSCLC therapy [Yahoo! Finance]
Low
Report
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4's NSCLC therapy [Yahoo! Finance]
10/4
09:17 am
xlo
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting [Yahoo! Finance]
Medium
Report
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting [Yahoo! Finance]
10/4
09:05 am
xlo
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Medium
Report
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
10/2
04:15 pm
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)